Table II.

Univariate and multivariate analyses for overall survival and progression-free survival.

A, Overall survival
	Univariate analysis (log-rank test)	Multivariate analysis (Cox test)
Characteristic	P-value	HR	P-value	95% CI
Age (≤60 vs. >60 years)	0.009	0.229	0.038	0.057–0.922
Sex (male vs. female)	0.525	–	–	–
ECOG (0–1 vs. 2–4)	0.377	–	–	–
CD10 (positive vs. negative)	0.924	–	–	–
BCL-6 (positive vs. negative)	0.453	0.612	0.468	0.163–2.303
BCL-2 (positive vs. negative)	0.328	0.549	0.427	0.125–2.409
Ki-67 (>90 vs. ≤90%)	0.037	0.414	0.162	0.120–1.424
Immunophenotype (GCB vs. non-GCB)	0.410	0.506	0.365	0.116–2.209
Chemotherapy (HD-MTX+Ara-C vs. HD-MTX+TMZ)	0.671	0.993	0.990	0.309–3.191
LDH (elevated vs. normal)	0.442	–	–	–
No. of lesions (1 vs. ≥2)	0.592	0.880	0.835	0.262–2.954
B, Progression-free survival
	Univariate analysis (log-rank test)	Multivariate analysis (Cox test)
Characteristic	P-value	HR	P-value	95% CI
Age (≤60 vs. >60 years)	0.141	0.566	0.237	0.220–1.456
Sex (male vs. female)	0.957	–	–	–
ECOG (0–1 vs. 2–4)	0.313	–	–	–
CD10 (positive vs. negative)	0.264	–	–	–
BCL-6 (positive vs. negative)	0.304	0.736	0.571	0.255–2.126
BCL-2 (positive vs. negative)	0.463	0.649	0.438	0.218–1.934
Ki-67 (>90 vs. ≤90%)	0.039	0.437	0.075	0.176–1.086
Immunophenotype (GCB vs. non-GCB)	0.131	0.398	0.109	0.129–1.228
Chemotherapy (HD-MTX+Ara-C vs. HD-MTX+TMZ)	0.459	1.063	0.898	0.422–2.675
LDH (elevated vs. normal)	0.779	–	–	–
No. of lesions (1 vs. ≥2)	0.740	1.021	0.967	0.387–2.696

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; HD-MTX + Ara-C, high-dose methotrexate + cytarabine; HD-MTX + TMZ, high-dose methotrexate + tomozolomide; OS, overall survival; PFS, progression-free survival; CI, confidence interval; HR, hazard ratio; CD10, cluster of differentiation 10; BCL, B cell lymphoma.